Business Description
Sichuan Kelun-Biotech is a Chinese drug development company focused on creating new treatments for cancer and immune-related diseases, with operations extending beyond China into global markets. The company has built a broad portfolio of next-generation therapies, with particular strength in antibody-drug conjugates targeting a range of solid tumors. It works alongside several international partners, including Merck Sharp & Dohme, to advance its pipeline through licensing and collaboration agreements. Founded in 2016 and based in Chengdu, it operates as part of the larger Sichuan Kelun Pharmaceutical group.
